{'fraction_non_alphanumeric': 0.02403846153846154, 'fraction_numerical': 0.003205128205128205, 'mean_word_length': 5.4051282051282055, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[NGS-based multi-gene panel testing in hematological malignancies: germline variants and related issues].

Gene panel test, which has been used in the field of solid tumors, is expected to be introduced in the field of hematopoietic tumors in the near future. Unintended germline variants may be detected due to the comprehensive nature of the gene panel test, and these are called "secondary findings." Additionally, it sometimes reveals that a person has germline variants that predispose the carriers to develop the disease. There are several impeding issues to be addressed regarding these germline variants, including detection methods, obtaining informed consent, scope of variants to be disclosed, and genetic counseling methods. In the field of hematopoietic tumors, the problem is further complicated by the possibility of detecting germline variants in donors because allogeneic hematopoietic stem cell transplantation constitutes an important treatment modality in this field. Thus, this paper aims to outline the issues related to germline variants in gene panel tests, which were discussed at the symposium "NGS-based multi-gene panel testing in hematology/oncology" at the annual meeting of the Japanese Society of Hematology in 2021.